Pharmacodynamic Evaluation of OV329 in Participants with Epilepsy and a Photo-Induced Generalized Epileptiform EEG-Response Phase 2 Proof-of-Concept.

2026-527114-23-00 · tracked via the Priya Life Science EU tracker

Sponsor

Ovid Therapeutics Inc.

Sponsor type

Pharmaceutical company

Therapeutic area

Nervous System Diseases

Decision date

03/08/2026

Enrollment target

Sites

Netherlands

Condition studied

Epilepsy

Investigational medicinal product(s)

Placebo for OV329OV329OV329

Eligibility

Age group

18-64 years, 65+ years

Sex

Female, Male

Primary endpoint

Change from Baseline in standardized photosensitivity range (SPR) on Day 1 (placebo) to post-dose OV329 on several days

Official registry record

This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View 2026-527114-23-00 on CTIS ↗ ← All trials in the EU